



PRESS RELEASE - For immediate release

Molsid Announces Successful Completion of Clinical Study for Its First Diagnostic Kit, ResiScreen® Staph, improving antimicrobial resistance detection

Lyon, France — Octobre 21, 2025 — Molsid today announced the successful completion of the clinical performance study for its first diagnostic kit, **ResiScreen® Staph**. This milestone marks a major step toward the commercial launch of the company's innovative solution for the reliable detection of β -lactam resistance in *Staphylococcus* strains.

The study was conducted in collaboration with the French National Reference Centre for Staphylococci (Hospices Civils de Lyon, France) under the supervision of Prof. Frédéric Laurent and Dr. Céline Dupieux-Chabert. It evaluated the performance of **ResiScreen® Staph** on 300 clinical isolates of *Staphylococcus aureus* and *Staphylococcus non-aureus*, confirming the kit's robustness, reliability, and clinical relevance.

Accurate detection of staphylococcal beta-lactamase remains a diagnostic challenge as phenotypic methods, such as the benzylpenicillin disc edge test and nitrocefin-based assays remain observer-dependent and can lack of sensitivity. Powered by Molsid's patented SmartID® fluorescent biotracer technology, **ResiScreen® Staph** overcomes the limitations of current methods for β -lactamase detection. It provides an easy-to-interpret binary readout with a broad-spectrum applicability to accurately detect *blaZ*-encoded penicillinase activity in staphylococci. The method is cost-effective, requiring minimal equipment and perfectly adapted to routine laboratory workflows. This capability represents a significant advance in the field of medical diagnostic, addressing a critical need for fast, reliable, and easy-to-interpret antimicrobial resistance detection in microbiology laboratories.

"This achievement represents a key milestone for Molsid, paving the way for the commercialization of **ResiScreen® Staph**," said Stéphane Gavaille, CEO of Molsid. "We are proud to bring to market an innovative and practical diagnostic tool that will directly support clinicians and microbiologists in the global effort to contain antimicrobial resistance."

With the successful validation of **ResiScreen® Staph**, Molsid reaffirms its mission to deliver next-generation diagnostic technologies that combine scientific excellence, clinical value, and operational simplicity. Eurobio Scientific will commercialize the product across key European territories.

About Molsid: Molsid develops and commercializes rapid diagnostic tools based on its innovative SmartID® biotracer platform, enabling phenotypic detection of antibiotic resistance. The company's mission is to accelerate antimicrobial resistance detection in clinical settings, helping to guide appropriate therapy choices.

Media Contacts

Stéphane Gavaille
+33 (0)7 69 74 37 16
stephane.gavaille@molsid.com
<https://molsid.com/>

MOLSID S.A.S. • Biopark • Bâtiment Bioserra 2 • 60F Avenue Rockefeller • 69008 LYON • FRANCE
contact@molsid.com • www.molsid.com

Molsid S.A.S. au capital de 238.320 Euros • RCS Lyon 841 552 730 • SIRET 841 552 730 00019 • NAF 7211Z